Roche Holding News

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Roche Holding AG 's Tarceva lung- cancer medicine won the backing of the U.K.'s health-cost agency after presenting data comparing the drug with AstraZeneca Plc 's Iressa, ... (more)

A number of other analysts have also recently weighed in on RHHBY. Analysts at JPMorgan Chase downgraded shares of Roche Holding from an "overweight" rating to a "neutral" rating in a research note to investors on Tuesday.

Separately, analysts at Citigroup downgraded shares of Roche Holding from a "buy" rating to a "neutral" rating in a research note to investors on Tuesday, February 14th.

Stock markets recovered around the world following an early stumble caused by election results in France and Greece that appeared to jeopardize Europe's plans for fighting its debt crisis.

A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies.

Swiss drug maker Roche Holding AG has ended development of a cholesterol drug that it had hoped could achieve blockbuster status.

From time to time, we will send you e-mail announcements on new features and special offers from The Wall Street Journal Online.

Roche Holding AG Monday said it stopped development of good cholesterol drug dalcetrapib for lack of efficacy, dealing a major blow to the Swiss drugmaker, which had hoped the drug could become a blockbuster with more than $1 billion in annual sales.